Pure Global
NCT06375213

Investigating Neurocognitive Disorders Epidemiology

King Chulalongkorn Memorial Hospital·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dementia,Cognitive Decline,Alzheimer Disease
Drug/Device/Intervention
Plasma tau phosphorylated at Thr217
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
King Chulalongkorn Memorial Hospital
Location
Pathum Wan, Thailand
Timeline & enrollment
Phase
N/A
Start date
Aug 24, 2023
End date
Aug 24, 2035
Enrollment
990 participants
Primary outcome

Progression to dementia,Changes in Sum of Boxes of the Clinical Dementia Rating Scale

Summary

This is a prospective cohort study with the main purpose of predicting progression
 neurocognitive disorders in Thai population. The main predictor variables to be evaluated are
 plasma phosphorylated tau (p-tau) level and cognitive test scores, which will be combined
 using statistical/computational modeling. Additionally, it seeks to evaluate biomarkers for
 diagnosing disease pathologies, understand their correlation with clinical outcomes, and
 explore the socioeconomic impact of neurocognitive disorders. The study invites both
 participants for biospecimen collection, structured interviews, and cognitive examinations
 and schedules follow-up visits annually or biennially.

ICD-10 classifications
Dementia in Alzheimer diseaseDementia in other diseases classified elsewhereDementia in other specified diseases classified elsewhereAlzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06375213
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06375213 through Pure Global AI's free database. This phase not specified trial is sponsored by King Chulalongkorn Memorial Hospital and is currently Recruiting. The study focuses on Dementia,Cognitive Decline,Alzheimer Disease. Target enrollment is 990 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.